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Prognostic Implication of EGFR, KRAS, and TP53 Gene
Mutations in a Large Cohort of Japanese Patients with
Surgically Treated Lung Adenocarcinoma
Takayuki Kosaka, MD,*† Yasushi Yatabe, MD,‡ Ryoichi Onozato, MD,*† Hiroyuki Kuwano, MD,†
and Tetsuya Mitsudomi, MD*‡
Introduction: Although mutation of the epidermal growth factor
receptor (EGFR) gene is predictive for the response to EGFR-tyrosine
kinase inhibitor, its prognostic impact for patients without EGFR-
tyrosine kinase inhibitor treatment remains controversial. We examined
for EGFR, KRAS or TP53 mutations in a consecutive large cohort of
patients with lung adenocarcinoma, and evaluated their prognostic impact.
Methods: We analyzed 397 patients with lung adenocarcinoma who
underwent potentially curative pulmonary resection. Total ribonu-
cleic acid was extracted and direct sequencing of each gene was
performed after reverse transcription-polymerase chain reaction.
Results: We found that 196 patients (49%) had EGFR mutations. Of
these, 83 were exon 19 deletions (42%) and 92 were L858R (47%).
Univariate analysis showed that patients with EGFR mutations
survived for a longer period than those without mutations (p 
0.0046). However, there was no difference in overall survival
between the patients with exon 19 deletion and those with L858R
(p  0.4144). Patients with KRAS mutations or TP53 mutations
tended to survive for a shorter period (p  0.2183 and 0.0230,
respectively). Multivariate analysis using the Cox proportional haz-
ards model revealed that smoking status (p  0.0310) and disease
stage (p  0.0001) were independent prognostic factors. However,
none of the gene mutations was independent prognostic factors
(EGFR, p  0.3225; KRAS, p  0.8500; TP53, p  0.3191).
Conclusions: EGFR, KRAS, and TP53 gene mutations were not
independently associated with the prognosis for Japanese patients
with surgically treated lung adenocarcinoma.
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Multiple genetic alterations result in the activation ofoncogenes and the inactivation of tumor suppressor
genes during the formation of lung adenocarcinoma. In par-
ticular, mutations of genes in the epidermal growth factor
receptor (EGFR) signaling pathway, such as EGFR, KRAS,
HER2, BRAF, and phosphatidyl inositol 3 kinase catalytic
alpha (PIK3CA), are thought to be important for the patho-
genesis of adenocarcinomas.1–4
Activating mutation of the EGFR gene was first re-
ported in 2004.5–7 EGFR mutations are more prevalent in
females, never smokers, patients of Asian ethnicity, and those
with histology of adenocarcinoma8. We previously showed
that about 50% of lung adenocarcinomas from Japanese
patients harbored EGFR mutations.1 Tumors with EGFR
mutations are highly sensitive to small molecule EGFR-
specific tyrosine kinase inhibitors (TKIs), such as gefitinib or
erlotinib. According to the published data for 1335 patients,
the response rate of non-small cell lung cancers (NSCLCs)
with EGFR mutations for EGFR-TKI was about 70%,
whereas those without mutations was about 10%.8 Further-
more, several retrospective studies showed that patients with
EGFR mutations have a significantly longer survival than
those without mutations when treated with EGFR-TKIs.9–12
These results indicate that the EGFR mutations are important
predictive factors for successful treatment with EGFR-TKIs.
However, prognostic impact of EGFR gene mutations in lung
adenocarcinoma remains controversial some investigators
claim that EGFR mutations are prognostic rather than pre-
dictive, because reports showed that patients with NSCLCs
harboring EGFR mutations survived for a longer period than
those without mutations irrespective of therapy (chemother-
apy with EGFR-TKIs or placebo).13,14 However, we identi-
fied previously that EGFR mutations did not affect the prog-
nosis for patients with adenocarcinoma who were not treated
with gefitinib.1 Similar results were reported from two inde-
pendent groups.15,16 Thus, prognostic impact of EGFR muta-
tions in the patients with NSCLCs remains controversial.
Activating mutation of the KRAS gene was one of the
earliest discoveries of genetic alteration in lung cancers,17 and
about 10% of NSCLCs of Japanese patients harbored KRAS
mutations.18–20 We and others reported the strictly mutually
exclusionary manner of EGFR and KRAS mutations.1,15 Sev-
eral meta-analyses revealed that KRAS mutations may be
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associated with shortened survival in patients with NSCLCs,
although sufficient confirmation in well designed multivariate
analysis has not been obtained.21,22 A similar tendency is seen
in the analysis of TP53 gene mutations, which is also thought
to be important in pathogenesis of lung adenocarcinomas and
many other types of human cancers.23,24
In this study, we examined for EGFR, KRAS, and TP53
mutations among a large cohort of patients with lung adeno-
carcinomas who underwent pulmonary resection in a single
institution and evaluated their prognostic implications.
PATIENTS AND METHODS
Patients
Primary tumor samples were obtained from 397 con-
secutive unselected patients with lung adenocarcinomas who
underwent potentially curative pulmonary resection at the
Department of Thoracic Surgery, Aichi Cancer Center Hos-
pital from May 2000 through December 2005. Appropriate
approval was given in advance by our institutional review
board and all patients gave written informed consent. Two
hundred and twenty-four patients from our previous report of
EGFR mutational analysis were included in this cohort.1
There were 201 males and 196 females with an age at
diagnosis ranging from 26 to 89 years (median 64). Two
hundred and forty-eight patients had stage I disease, 44 stage
II, 96 stage III, and 9 stage IV. There were 189 never smokers
and 208 ever smokers including current and former smokers.
Fifty-six patients had received gefitinib treatment at a daily
dose of 250 mg for their recurrent disease. The median
follow-up period was 991 days (range, 4–2286).
EGFR Mutational Analysis of Lung
Adenocarcinoma Specimens
Tumor samples were obtained at the time of surgery,
rapidly frozen in liquid nitrogen, and stored at80°C. Frozen
tissues of the tumor specimens were grossly dissected to
enrich tumor cells as much as possible by a surgical pathol-
ogist (Y.Y.). Total ribonucleic acid was isolated using
RNeasy kits (Qiagen, Valencia, CA).
The first 4 exons (exons 18–21) of the 7 exons (exons
18–24) that code for the TK domain of the EGFR gene
were amplified with primers F1 (5-AGCTTGTGGAGC-
CTCTTACACC-3) and R1 (5-TAAAATTGATTCCAAT-
GCCATCC-3), in a one-step reverse transcription–poly-
merase chain reaction (RT-PCR) amplification using
QIAGEN OneStep RT-PCR Kits (Qiagen, Valencia, CA), as
previously described.1 The cDNA sequence of EGFR gene
was obtained from GenBank (accession number NM005228).
RT-PCR conditions were: one cycle of 50°C for 30 minutes
and 95°C for 15 minutes; 40 cycles of 94°C for 50 seconds,
62°C for 50 seconds, and 72°C for 1 minute; followed by one
cycle of 72°C for 10 minutes. RT-PCR products were diluted
and cycle-sequenced using the Big Dye Terminator v3.1/1.1
cycle sequencing kit (Applied Biosystems, Foster City, CA).
The sequencing reaction products were electrophoresed using
an ABI PRISM 3100 system (Applied Biosystems). Both
forward and reverse sequences were analyzed with the basic
local alignment search tool, and the chromatograms were
analyzed by manual review.
KRAS and TP53 Gene Mutational Analysis
KRAS mutations and TP53 mutations were analyzed as
previously reported.20,25 Briefly, KRAS gene (exons 1and 2)
and TP53 gene (exons 4 through 10) were amplified and
sequenced directly using an ABI PRISM 310 Genetic Ana-
lyzer (Applied Biosystems). KRAS was analyzed for 254
tumors and TP53 was analyzed for 376 tumors. Because this
study represents a retrospective review of our cohort, we
could not obtain the result of all 3 mutational statuses of 397
patients.
Statistical Analysis
For comparisons of proportions, the 2 test or Fisher
exact test were used. The Kaplan-Meier method was em-
ployed to estimate the probability of survival as a function of
time, and survival differences were analyzed by the log-rank
test. The two-sided significance level was set at p 0.05. The
Cox proportional hazards modeling technique was applied for
multivariate analysis of the overall survival. All analyses
were performed using a StatView (version 5, SAS institute
Inc., Cary, NC).
RESULTS
Gene Mutations in Unselected Lung
Adenocarcinoma Specimens
EGFR gene mutations were detected in 196 of 397
patients (49.4%). There were 105 point mutations, 83 dele-
tion mutations, and 12 duplication/insertion mutations. De-
tails of these mutations are shown in Figure 1.
Ninety-two patients had L858R. Six patients had point
mutations occurring at codon 719 in exon 18 resulting in the
substitution of glycine with aranine, serine, or cysteine
(G719X). Two patients had point mutations occurring at
codon 768 in exon 20 and one had point mutation occurring
at codon 861 in exon 21. Almost all of the 83 deletion
mutations occurred around the 5 amino acid residues ELREA
at codons 746–750 in exon 19. About half (39/83) of deletion
mutations were simple deletions of ELREA. Thirty-four of
the deletions were coupled with point mutations or insertions,
yielding various changes in amino acid sequences. In 12
duplication/insertion mutations, 1 was in exon 19, and 11
were in exon 20.
In the 196 patients with mutations, 92 of the mutations
were L858R (47%) and 83 were exon 19 deletions (42%),
altogether accounting for about 90% of all the EGFR muta-
tions found. The 4 major classes of mutations (i.e., L858R,
deletions, mutations at codon 719, and duplications/inser-
tions) never occurred simultaneously, confirming our previ-
ous observation.1
KRAS mutations were present in 32 of 254 patients
(12.6%). Twenty-seven occurred in codon 12, 2 were in
codon 13, and 3 were in codon 61. TP53 mutations were
present in 142 of 376 patients (37.8%). KRAS mutations were
never found in tumors with EGFR mutations, showing a
mutually exclusive relationship (p  0.0001; Table 1). In
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TABLE 1. Relationship Between Three Gene Mutations and Clinicopathological Features
Variables Category
EGFR KRAS TP53
Mut Wt p Mut Wt p Mut Wt p
n 196 (49%) 201 32 (13%) 222 142 (38%) 234
Sex Male 76 (38%) 125 0.0001 24 (19%) 101 0.0018 91 (48%) 99 0.0001
Female 120 (61%) 76 8 (6%) 121 51 (27%) 135
Age 64 87 (46%) 103 0.1716 18 (15%) 100 0.2437 77 (42%) 105 0.0785
64 109 (53%) 98 14 (10%) 122 65 (34%) 129
Smoking status Never 128 (68%) 61 0.0001 8 (6%) 116 0.0114 49 (28%) 129 0.0001
Current or former 68 (33%) 140 24 (18%) 106 93 (47%) 105
Stage I 127 (51%) 121 0.3443 17 (11%) 139 0.6986 77 (33%) 158 0.0098
II–IV 69 (46%) 80 15 (15%) 83 65 (46%) 76
Differentiation Well to mod 148 (57%) 113 0.0001 21 (12%) 148 0.8634 75 (30%) 174 0.0001
Poor 37 (32%) 80 11 (15%) 63 62 (57%) 46
KRAS Mut 0 (0%) 33 0.0001 — — — — — —
Wt 127 (57%) 95 — — — — — —
TP53 Mut 64 (45%) 78 0.1165 15 (15%) 86 0.4241 — — —
Wt 125 (53%) 109 17 (11%) 132 — — —
Mod, moderately; Mut, mutation; n, number; Wt, wild-type; EGFR, epidermal growth factor receptor.
exon category amino acid 
change
number
18 G719X G719A 3
G719S 2
G719C 1
20 others S768I 1
S768I + V769L 1
21 L858R L858R 89
L858R + D761Y 1
L858R + S768I 1
L858R + T790M 1
others L861Q 1
740       750       760
KIPVAIKELREATSPKANKEILD
number
KIPVAIK.....TSPKANKEILD 39
KIPVAIK...RPTSPKANKEILD 1
KIPVAIK.....ASPKANKEILD 1
KIPVAIK....IPSPKANKEILD 1
KIPVAIK....VASPKANKEILD 1
KIPVAIK......APKANKEILD 1
KIPVAIK......VPKANKEILD 1
KIPVAIKE...STSPKANKEILD 13
KIPVAIKE...PTSPKANKEILD 5
KIPVAIKE...QTSPKANKEILD 1
KIPVAIKE.....SPKANKEILD 3
KIPVAIKE....QSPKANKEILD 2
KIPVAIKE....PSPKANKEILD 1
KIPVAIKE......PKANKEILD 3
KIPVAIKE....QHPKANKEILD 2
KIPVAIKE....QRPKANKEILD 1
KIPVAIKELREA.....NK.ALD 1
KIPVAIKELREA........NLD 1
KIPVAIKELREA........SLD 1
KIPVAIKELREA.........LD 1
Exon 19
740       750       760
KIPVAIKELREATSPKANKEILD
number
KIPVAIKIPVAIKELREATSPKANKEILD 1
760      770
KEILDEAYVMASVDNPHVCR
number
KEILDEAFQEAYVMASVDNPHVCR 1 
KEILDEAYVMATLASVDNPHVCR 1
KEILDEAYVMASVASVDNPHVCR 2
KEILDEAYVMASVGVDNPHVCR 1
KEILDEAYVMASVGFNPHVCR 1
KEILDEAYVMASVGYNPHVCR 1
KEILDEAYVMASVDSVPNPHVCR 1
KEILDEAYVMASVDNHPHVCR 1
KEILDEAYVMASVDNPDNPHVCR 1
KEILDEAYVMASVDNPHVHVCR 1
Exon 19
Exon 20
 A  Point mutations
 B  Deletions  C  Insertions/Duplications
FIGURE 1. Details of amino acid changes of epi-
dermal growth factor receptor (EGFR) gene muta-
tions. A, Details of point mutations, B, Details of
deletion mutations, C, Details of insertion/duplica-
tion mutations.
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contrast, TP53 mutations and EGFR or KRAS mutations
appeared to occur independently (p  0.1165 and 0.4241,
respectively).
Relationships Between Mutations
and Clinicopathological Features
EGFR mutations were significantly more frequent in
females (61%) than in males (38%; p  0.0001), in never-
smokers (68%) than in smokers (33%; p  0.0001), and in
more prevalent among patients with well to moderately dif-
ferentiated adenocarcinoma (57%) than in those with poorly
differentiated adenocarcinoma (32%; p  0.0001; Table 1).
In contrast, KRAS mutations were significantly more frequent
in males (19%) than in females (6%; p  0.0018) and in
smokers (18%) than in never-smokers (6%; p 0.0114). The
incidences of TP53 mutations also contrasted with those for
EGFR mutations. They were significantly more frequent in
males (48%) than in females (27%; p  0.0001), in smokers
(18%) than in never-smokers (6%; p  0.0001), in patients
with poorly differentiated adenocarcinoma (57%) than in
those with well to moderately differentiated adenocarcinoma
(30%), and in those with advanced stage tumor (46%) than
with early stage tumor (33%; p  0.0098). There was no
significant difference between the patients with the 2 major
types of EGFR mutations (deletion and L858R) in clinico-
pathological features (Table 2).
When we divided smokers into three categories accord-
ing to the amount of smoking exposure by pack-year, there
was a trend showing that the higher the exposure, the lower
the incidence of EGFR mutations (Figure 2). In contrast, the
incidences of KRAS and TP53 mutations increased along with
increased smoking exposure.
Survival Analysis
Many studies have indicated that patients with EGFR
mutations survived for a longer period than those without
EGFR mutations after gefitinib treatment. Therefore, we
performed survival analysis, excluding 56 patients who were
treated with gefitinib when they had recurrent diseases. Uni-
variate analysis showed that never-smokers, patients with
early-stage and with well to moderately differentiated tumors
survived significantly for a longer period, and females tended
to survive longer (Figures 3A–D). Patients with EGFR mu-
tations also survived significantly for a longer period than
those without the mutations (p  0.0046 by log-rank test;
Figure 4A). The result of survival analysis using only 2 major
mutations (deletions and L858R) compared with wild type
was almost same as the result of all EGFR mutations (p 
0.0075; Figure 4B). There was no difference in overall
survival between the patients with exon 19 deletions and
those with L858R mutations (p  0.4144; Figure 4C). In
contrast, there was a tendency that patients with KRAS mu-
tations survived for a shorter period than those without
mutations, whereas there was no statistically significant dif-
ference (p  0.2183; Figure 4D). Patients with TP53 muta-
tions survived significantly for a shorter period than those
without the mutations (p 0.0230; Figure 4F). There was no
significant difference between patients with EGFR mutations
and those with KRAS mutations in 208 patients who were able
to be performed both mutational analyses (p  0.0713;
Figure 4E).
Multivariate analysis using Cox proportional hazards
model revealed that being a never-smoker (p  0.0310) and
disease stage (p  0.0001) were independent prognostic
factors (Table 3). However, none of the gene mutations was
an independent prognostic factor (EGFR, p  0.3225; KRAS,
p  0.8500; TP53, p  0.3191).
DISCUSSION
We found that none of the, KRAS, and TP53EGFR,
KRAS, and TP53 genes was an independent prognostic factor
when tested by multivariate analysis, whereas they had sig-
TABLE 2. Relationship Between two Major Types of EGFR Mutations
and Clinicopathological Features
Variables Category All Mutations Exon 19 Deletion L858R p
n 196 83 92
Sex Male 76 32 (39%) 34 (37%) 0.8276
Female 120 51 (61%) 58 (63%)
Smoking status Never 128 56 (67%) 63 (68%) 0.8865
Current or former 68 27 (33%) 29 (32%)
Differentiation Well to mod 148 64 (82%) 72 (83%) 0.9051
Poor 37 14 (18%) 15 (17%)
Mod, moderately; n, number.
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FIGURE 2. Incidence of epidermal growth factor receptor
(EGFR), KRAS, and TP53 gene mutations according to smok-
ing dose in 250 patients for whom we performed mutational
analyses of all three genes.
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nificant prognostic value (except for KRAS) by univariate
analysis. We consider that statistical significance in the uni-
variate analysis might have been caused by confounding with
other prognostic factors such as sex, smoking status, and
tumor differentiation. EGFR mutations were more prevalent
in females, in never smokers, or in well to moderately
differentiated tumors, which are thought to be predictors of
better survival among patients with NSCLCs. In contrast,
KRAS and TP53 mutations were more prevalent in males or
in smokers, which are thought to be predictors of worse
survival. When we adjusted for these prognostic factors,
the three genes lost their prognostic impact by univariate
analysis.
In this study, we focused on the prognostic implications
of EGFR mutation, not the predictive implications. Therefore
we excluded the patients who received gefitinib from the
current survival analysis. However, there is possibility that
removal of these patients introduced an adverse bias as they
were patients who recurred therefore may be more likely to
have had worse survival. The mutation frequencies of EGFR,
KRAS, and TP53 in patients with gefitinib treatment were
64%, 10%, and 49%, respectively (those of patients without
gefitinib treatment were 49%, 13%, and 38%, respectively).
Patients with gefitinib had a higher prevalence of EGFR
mutations (64% versus 49%). This was due to the tendency to
select patients with favorable characteristics; i.e., adenocar-
cinoma, female, and never-smokers.
Recently, Marks et al.26 have reported a prognostic
analysis of EGFR and KRAS mutations in 296 patients who
underwent resection in their institution for stage I–III lung
adenocarcinomas, without any treatment with TGFR-TKIs.
They found by univariate analysis that patients with EGFR
mutations survived for a longer period than those without
mutations (p  0.031), and the patients with KRAS mutations
survived for a shorter period (the statistical value was not
shown). These results are consistent with our results. They
described that the survival difference approached significance
on multivariate analysis, whereas there was no detailed de-
scription about the p value, or which factors they used for
multivariate analysis. Why such a difference on multivariate
analysis occurred was not clear. The difference between races
or the difference of the mutation frequency might be related
about it.
We confirmed that the incidence of EGFR mutations
decreased along with smoking exposure, as indicated in our
previous report.1 We found that the incidences of KRAS and
TP53 mutations increased along with the increasing of smok-
ing exposure, in contrast to the tendency for EGFR mutations.
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FIGURE 3. Effect of clinicopatho-
logical features on the survival of
the patients with pulmonary ade-
nocarcinoma without gefitinib
treatment. A, Overall survival in
relation to smoking status, B, Over-
all survival in relation to tumor pa-
thology stage, C, Overall survival in
relation to sex, D, Overall survival
in relation to tumor differentiation.
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Smoking status was a significant prognostic factor shown by
multivariate analysis in this study. The confounding of mu-
tational status and smoking status is very important for
survival analysis. However, the apparent negative correlation
with EGFR mutations and smoking dose arose from the
statistical dilution of EGFR-mutated tumors with the in-
creased of tumors with wild-type EGFR that occurs along
with increasing rate of smoking dose. We found this effect in
our recent case-control study.27 The odds ratio for the patients
with wild-type EGFR increased significantly with the in-
creased smoking exposure. In contrast, no significant change
in risk was observed for the patients with EGFR mutations.
Cumulative exposure to smoking showed a linearly increased
risk for EGFR-wild-type NSCLCs only. These results indi-
cate that EGFR mutations are caused by carcinogens other
than those found in tobacco smoke.
Many reports have revealed that the response rates of
patients with EGFR mutations for EGFR-TKIs treatment are
high, and that patients with EGFR mutations survived for
longer periods than those without mutations.8 Considering
these results along with our limited current analyses, the
presence of EGFR mutations would be a predictive factor for
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FIGURE 4. Effect of gene muta-
tions for the survival of the patients
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dermal growth factor receptor
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the gefitinib treatment, but is not an independent prognostic
factor for pulmonary adenocarcinomas without gefitinib treat-
ment. To determine whether EGFR mutations indeed have a
predictive impact for treatment with EGFR-TKIs and that
they do not have a prognostic impact without treatment,
randomized prospective clinical trials are necessary. The
West Japan Thoracic Oncology Group launched a phase III
clinical trial (WJTOG3405) comparing gefitinib monotherapy
with cisplatin plus docetaxel in lung-cancer patients with
EGFR mutation. Primary end point is progression-free
survival, to avoid confounding by possible crossover be-
tween 2 arms and the sample size is 200 patients with
EGFR mutations.
Shigematsu et al.15 reported that patients with NSCLCs
harboring L858R mutations survive for significantly longer
than those with exon 19 deletions who did not receive
EGFR-TKI. However, we found no such significant differ-
ence, in agreement with Sugio et al. and Marks et al.16,26 One
possible explanation for this discrepancy could be the asso-
ciation between the types of mutations and clinicopatholog-
ical features. There was almost no difference in the incidence
of predictors of better survival—sex, smoking status, or
tumor differentiation—between exon19 deletions and L858R
mutations in our cohort. For patients treated with RGFR-TKI,
several authors claims that patients with exon 19 deletions
have better prognosis than those with L858R.28,29 It is sug-
gested that the treatment with EGFR-TKI contributes to the
prognosis of patients with EGFR mutations, and the degree of
contribution might be different according to the types of
mutation.
In conclusion, we found that none of the mutations
commonly found in adenocarcinoma of the lung; i.e., EGFR,
KRAS and TP53 mutations, was independently associated
with prognosis of patients, when adjusted by clinical factors
such as smoking history, stage, differentiation grade, and sex.
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